Skyrizi and Breathing - slowed or stopped - a phase IV clinical study of FDA data

Summary:

Breathing - slowed or stopped is reported as a side effect among people who take Skyrizi (risankizumab-rzaa), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Amitriptyline Hydrochloride, and have Psoriasis.

The phase IV clinical study analyzes which people have Breathing - slowed or stopped when taking Skyrizi. It is created by eHealthMe based on reports of 45,344 people who have side effects when taking Skyrizi from the FDA, and is updated regularly.

What is Skyrizi?

Skyrizi has active ingredients of risankizumab-rzaa. eHealthMe is studying from 45,385 Skyrizi users. Check the latest studies of Skyrizi.

What is Breathing - slowed or stopped?

Breathing - slowed or stopped is found to be associated with 1,226 drugs and 2,167 conditions by eHealthMe. Check the latest studies of Breathing - slowed or stopped.

On Jul, 06, 2026

45,344 people reported to have side effects when taking Skyrizi.
Among them, 12 people (0.03%) have Breathing - slowed or stopped.

Could Skyrizi cause Breathing - slowed or stopped?

Among these 12 people:

How long have people been on Skyrizi when they have Breathing - slowed or stopped? *

What is the gender of people who have Breathing - slowed or stopped when taking Skyrizi? *

female: 33.33 %
male: 66.67 %

What is the age of people who have Breathing - slowed or stopped when taking Skyrizi? *

What are other drugs people take besides Skyrizi? *

Promethazine Hydrochloride: 1 person, 8.33%
Prednisone: 1 person, 8.33%
Pantoprazole Sodium: 1 person, 8.33%
Ozempic: 1 person, 8.33%
Gabapentin: 1 person, 8.33%
Amitriptyline Hydrochloride: 1 person, 8.33%

What are other side effects people have besides Breathing - slowed or stopped? *

Malaise (a feeling of general discomfort or uneasiness): 6 people, 50.00%
Loss Of Consciousness: 4 people, 33.33%
Hypoxic-Ischaemic Encephalopathy (a condition that occurs when the entire brain is deprived of an adequate oxygen supply, but the deprivation isn't total): 3 people, 25.00%
Speech Impairment (Adult) (inability to speak (adult)): 3 people, 25.00%
Gaze Palsy (disorders affecting the ability to move both eyes in the same direction): 3 people, 25.00%
Seizures (abnormal excessive or synchronous neuronal activity in the brain): 3 people, 25.00%
Encephalopathy (functioning of the brain is affected by some agent or condition): 3 people, 25.00%
Asphyxia (a condition in which there is an extreme decrease in the concentration of oxygen in the body): 3 people, 25.00%
Encephalitis (inflammation of the brain): 3 people, 25.00%
Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 3 people, 25.00%

What are the existing conditions these people have? *

Psoriasis (immune-mediated disease that affects the skin): 11 people, 91.67%
Stable Angina (a constant chest pain): 3 people, 25.00%
Oedema Peripheral (superficial swelling): 3 people, 25.00%
Dyslipidaemia (abnormal amount of lipids): 3 people, 25.00%
Diabetes: 3 people, 25.00%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Skyrizi and have Breathing - slowed or stopped?

- Check whether Breathing - slowed or stopped is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Skyrizi:

Skyrizi (45,385 reports)

Browse all side effects of Skyrizi:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Breathing - slowed or stopped:

Breathing - slowed or stopped (1,226 drugs)

Browse all the conditions that are associated with Breathing - slowed or stopped:

Breathing - slowed or stopped (2,167 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on risankizumab-rzaa (the active ingredients of Skyrizi) and Skyrizi (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.